Technology
Health
Pharmaceutical

Principia Biopharma

$30.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.47 (-1.53%) Today
+$0.55 (1.84%) After Hours

Why Robinhood?

You can buy or sell PRNB and other stocks, options, ETFs, and crypto commission-free!

About

Principia Biopharma Inc. Common Stock, also called Principia Biopharma, is a biopharmaceutical company, which engages in design and development oral therapies to patients with significant unmet medical needs in immunology and oncology. Read More It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline include PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.

Employees
69
Headquarters
South San Francisco, California
Founded
2008
Market Cap
732.23M
Price-Earnings Ratio
Dividend Yield
Average Volume
119.69K
High Today
$31.16
Low Today
$29.85
Open Price
$30.93
Volume
79.66K
52 Week High
$38.34
52 Week Low
$22.00

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Medical
2018 IPO
US
North America

News

Yahoo FinanceMay 9

Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 2019 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 15, 2019, at 1:00pm PT (4:00pm ET) at the Encore Hotel in Las Vegas, Nevada. The presentation will be available via li...

17
Yahoo FinanceMay 7

Principia Biopharma Reports First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced financial results for the first quarter ended March 31, 2019. “In 2019, we are focused on executing our value-creating clinical development initiatives, including enrollment of our global Phase 3 trial in patients with pemphigus, ...

8
Yahoo FinanceMay 7

Here’s What Hedge Funds Think About Principia Biopharma Inc. (PRNB)

16

Earnings

-$0.62
-$0.29
$0.04
$0.37
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.